ClinicalTrials.gg
CompletedNCT02472795Updated Jul 29, 2026Results posted

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

A Phase 1/2 interventional study of Matching placebo and Cenerimod in Systemic Lupus Erythematosus, sponsored by Viatris Innovation GmbH. Completed at 18 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Lupus Erythematosus, Systemic with a site in Russia — none open to participants now, 3 under way, 2 of them phase 3. Lupus Erythematosus, Systemic · Russia.

Enrollment
9th of 11
105 · median 261
Started
2015
the only one that year
Phase 1/2
2 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
2 of 12
Viatris Innovation GmbH

Among the 12 studies in Lupus Erythematosus, Systemic with a site in Russia, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2015, is one of 2 in phase 1/2, and was the 3rd registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

None of the 12 studies in Lupus Erythematosus, Systemic with a site in Russia is open now. The open studies under Lupus Erythematosus, Systemic, anywhere →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Lupus Erythematosus, Systemic with a site in Russia as a file.
02

Study summary

International trial to evaluate the biological activity and safety of cenerimod (ACT-334441) in systemic lupus erythematosus (SLE) patients.

Read the detailed description

This multicentre, double-blind, placebo-controlled study will have a staggered approach (Part A and B).

In part A, eligible patients will be randomly assigned (1:1:1:1) to once daily oral administration of cenerimod (0.5, 1, 2 mg) or placebo. After all patients have completed 4 weeks of treatment during part A, an Independent Data Monitoring Committee will review non-blinded data in an interim analysis to evaluate the safety profile of cenerimod and recommend whether the study could proceed to part B.

In part B, additional patients will be randomized (3:1) to once daily oral administration of cenerimod 4 mg or placebo.

All participants will receive study medication for 12 weeks.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Systemic lupus erythematosus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants aged 18 to 65 years with established SLE. Participants must have active SLE, Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score of at least 2 points for musculoskeletal or mucocutaneous manifestations and history or presence at screening of positive anti-nuclear antibodies (ANA) or anti-double-stranded DNA (anti-dsDNA) antibodies.
  • Enrolled participants must be treated with background SLE medications.

Exclusion criteria

Exclusion Criteria:

  • Participants with significant medical conditions or therapies for such conditions (e.g., cardiovascular, pulmonary, immunological, hepatic, ophthalmological, infection and infection risks, history or presence of , history or presence of bone marrow or solid organ transplantation) or lactating or pregnant women.
  • Participants with severe SLE disease or with medical or surgical conditions that, in the opinion of the investigator, would put the subject at risk by participating in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Cenerimod 0.5 mg (Part A)

    Participants will receive cenerimod 0.5 mg capsules orally once daily for 12 weeks.

    Drug: Cenerimod

  • Experimental
    Cenerimod 1 mg (Part A)

    Participants will receive cenerimod 1 mg capsules orally once daily for 12 weeks.

    Drug: Cenerimod

  • Experimental
    Cenerimod 2 mg (Part A)

    Participants will receive cenerimod 2 mg capsules orally once daily for 12 weeks.

    Drug: Cenerimod

  • Experimental
    Cenerimod 4 mg (Part B)

    Participants will received cenerimod 4 mg capsules orally once daily for 12 weeks. This treatment arm will start after all patients in Part A have completed 4 weeks of placebo, 0.5 mg, 1 mg and 2 mg cenerimod treatment.

    Drug: Cenerimod

  • Placebo comparator
    Matching placebo (Part A and B)

    Capsules of matching placebo taken orally once daily for 12 weeks.

    Drug: Matching placebo

Interventions

  • DrugMatching placebo

    One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).

    Also known as: Placebo

  • One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).

    Also known as: ACT-334441

06

What researchers measure

Primary outcomes

  1. Change in Total Lymphocyte Count From Baseline to End-of-treatment (EOT)

    The primary objective of the clinical study was to asses whether cenerimod could reduce the number of circulating lymphocytes in the bloodstream of people with systemic lupus erythematosus (SLE). The change was defined as: Total lymphocyte count at end-of-treatment (EOT) minus total lymphocyte count at baseline. A negative change over time indicates that the number of peripheral circulating lymphocytes has decreased. The reduction of the total lymphocyte count over a treatment period indicates a pharmacodynamic effect. The value at baseline was defined as the last non-missing value obtained from a sample taken prior to the first study treatment intake. End-of-treatment (EOT) was defined as the last post-baseline value with treatment for at least 21 days up to Week 12.

    Time frame: Baseline to end-of-treatment (EOT) (up to 12 weeks)

  2. Change in Total Lymphocyte Count From Baseline to Each Post-baseline Assessment

    The primary objective of the clinical study was to assess whether cenerimod could reduce the number of circulating lymphocytes in the bloodstream of people with systemic lupus erythematosus (SLE). The change was defined as: Total lymphocyte count at visit minus total lymphocyte count at baseline. A negative change over time indicates that the number of peripheral circulating lymphocytes has decreased. The reduction of the total lymphocyte count over a treatment period indicates a pharmacodynamic effect. The value at baseline was defined as the last non-missing value obtained from a sample taken prior to the first study treatment intake. End-of-treatment (EOT) was defined as the last post-baseline value with treatment for at least 21 days up to Week 12.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, end-of-treatment Visit (up to 12 weeks)

07

Results

Posted Feb 26, 2020
Limitations and caveats
This study is the first to investigate short-term cenerimod treatment in patients with mild to moderate systemic lupus erythematosus (SLE).

Participant flow

This study was conducted at 18 sites in 6 countries between 1 June 2015 and 28 February 2017, 105 patients signed consent and 67 were randomized to a study treatment: 49 in part A (randomized 1:1:1:1 to receive cenerimod 0.5, 1, 2 mg or placebo) and 18 in part B (randomized 3:1 to receive cenerimod 4 mg or placebo).

Participant flow — Overall Study
MilestoneCenerimod 0.5 mg (Part A)Cenerimod 1 mg (Part A)Cenerimod 2 mg (Part A)Cenerimod 4 mg (Part B)Matching Placebo (Part A and B)
Started1212131317
Pharmacodynamic set1210131316
Modified pharmacodynamic analysis set121013916
Completed1211131314
Not completed01003
Withdrew: Adverse event01002
Withdrew: Withdrawal by subject00001

Outcome measures

PrimaryChange in Total Lymphocyte Count From Baseline to End-of-treatment (EOT)

The primary objective of the clinical study was to asses whether cenerimod could reduce the number of circulating lymphocytes in the bloodstream of people with systemic lupus erythematosus (SLE). The change was defined as: Total lymphocyte count at end-of-treatment (EOT) minus total lymphocyte count at baseline. A negative change over time indicates that the number of peripheral circulating lymphocytes has decreased. The reduction of the total lymphocyte count over a treatment period indicates a pharmacodynamic effect. The value at baseline was defined as the last non-missing value obtained from a sample taken prior to the first study treatment intake. End-of-treatment (EOT) was defined as the last post-baseline value with treatment for at least 21 days up to Week 12.

Time frame:
Baseline to end-of-treatment (EOT) (up to 12 weeks)
Reported as:
Mean · 10^9 cells/L
Change in Total Lymphocyte Count From Baseline to End-of-treatment (EOT)
10^9 cells/LCenerimod 0.5 mg (Part A)Cenerimod 1 mg (Part A)Cenerimod 2 mg (Part A)Cenerimod 4 mg (Part B)Matching Placebo
Change in Total Lymphocyte Count From Baseline to End-of-treatment (EOT)-0.26 ± 0.48-0.96 ± 0.68-0.86 ± 0.61-0.87 ± 1.24-0.33 ± 0.72
Statistical analysis
  • Cenerimod 0.5 mg (Part A) vs Matching Placebo · ANCOVA · p = 0.39 · Mean difference (final values): -0.17 · 95% CI -0.56 to 0.22
  • Cenerimod 1 mg (Part A) vs Matching Placebo · ANCOVA · p = 0.02 · Mean difference (final values): -0.5 · 95% CI -0.91 to 0.09
  • Cenerimod 2 mg (Part A) vs Matching Placebo · ANCOVA · p = 0.004 · Mean difference (final values): -0.57 · 95% CI -0.95 to -0.19
  • Cenerimod 4 mg (Part B) vs Matching Placebo · ANCOVA · p = 0.06 · Mean difference (final values): -0.37 · 95% CI -0.75 to 0.02
PrimaryChange in Total Lymphocyte Count From Baseline to Each Post-baseline Assessment

The primary objective of the clinical study was to assess whether cenerimod could reduce the number of circulating lymphocytes in the bloodstream of people with systemic lupus erythematosus (SLE). The change was defined as: Total lymphocyte count at visit minus total lymphocyte count at baseline. A negative change over time indicates that the number of peripheral circulating lymphocytes has decreased. The reduction of the total lymphocyte count over a treatment period indicates a pharmacodynamic effect. The value at baseline was defined as the last non-missing value obtained from a sample taken prior to the first study treatment intake. End-of-treatment (EOT) was defined as the last post-baseline value with treatment for at least 21 days up to Week 12.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, end-of-treatment Visit (up to 12 weeks)
Reported as:
Mean · 10^9 cells/L
Change in Total Lymphocyte Count From Baseline to Each Post-baseline Assessment
10^9 cells/LCenerimod 0.5 mg (Part A)Cenerimod 1 mg (Part A)Cenerimod 2 mg (Part A)Cenerimod 4 mg (Part B)Matching Placebo
Baseline visit1.37 ± 0.521.71 ± 0.821.62 ± 0.751.88 ± 0.771.65 ± 0.88
Week 2 visit-0.13 ± 0.56-0.48 ± 0.56-0.52 ± 1.03-1.09 ± 0.65-0.16 ± 0.75
Week 4 visit-0.28 ± 0.42-0.69 ± 0.76-0.86 ± 0.63-0.68 ± 1.32-0.33 ± 0.69
Week 8 Visit-0.28 ± 0.60-0.92 ± 0.60-0.89 ± 0.68-1.03 ± 1.12-0.09 ± 0.82
Week 12 visit-0.26 ± 0.48-0.72 ± 1.03-0.86 ± 0.61-0.87 ± 1.24-0.29 ± 0.73
End-of-treatment visit-0.26 ± 0.48-0.72 ± 1.03-0.86 ± 0.61-0.87 ± 1.24-0.30 ± 0.71
Post-hocChange in Total Lymphocyte Count From Baseline to End-of-treatment (EOT) Based on Pharmacokinetic Cthrough Profiles

The change was defined as: Total lymphocyte count at end-of-treatment (EOT) minus total lymphocyte count at baseline. A negative change over time indicates that the number of peripheral circulating lymphocytes has decreased. The value at baseline was defined as the last non-missing value obtained from a sample taken prior to the first study treatment intake. End-of-treatment (EOT) was defined as the last post-baseline value with treatment for at least 21 days up to Week 12. The modified pharmacodynamics analysis set includes all participants who: * received at least 21 days of study treatment \& * with lymphocyte count measurements at baseline and post-baseline (namely, one sample taken at least 21 days after the first study treatment intake and no later than 7 days after the last study treatment intake with no treatment interruption documented in the first 21 days) \& * with cenerimod plasma concentrations at Week 4 consistent with expectations.

Time frame:
Baseline to end-of-treatment (EOT) (up to 12 weeks)
Reported as:
Mean · 10^9 cells/L
Change in Total Lymphocyte Count From Baseline to End-of-treatment (EOT) Based on Pharmacokinetic Cthrough Profiles
10^9 cells/LCenerimod 0.5 mg (Part A)Cenerimod 1 mg (Part A)Cenerimod 2 mg (Part A)Cenerimod 4 mg (Part B)Matching Placebo
Change in Total Lymphocyte Count From Baseline to End-of-treatment (EOT) Based on Pharmacokinetic Cthrough Profiles-0.26 ± 0.48-0.96 ± 0.68-0.86 ± 0.61-1.48 ± 0.73-0.32 ± 0.72
Statistical analysis
  • Cenerimod 0.5 mg (Part A) vs Matching Placebo · ANCOVA · p = 0.2837 · Mean difference (final values): -0.145 · 95% CI -0.413 to 0.123
  • Cenerimod 1 mg (Part A) vs Matching Placebo · ANCOVA · p = 0.0006 · Mean difference (final values): -0.515 · 95% CI -0.797 to -0.234
  • Cenerimod 2 mg (Part A) vs Matching Placebo · ANCOVA · p = 0.0001 · Mean difference (final values): -0.565 · 95% CI -0.825 to -0.305
  • Cenerimod 4 mg (Part B) vs Matching Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -0.880 · 95% CI -1.173 to -0.586
Post-hocAbsolute Values of Total Lymphocyte Count at Each Analysis Visit

The primary objective of the clinical study was to see whether cenerimod could reduce the number of circulating lymphocytes in the bloodstream of people with systemic lupus erythematosus (SLE). The reduction of the total lymphocyte count over a treatment period indicates a pharmacodynamic effect. The modified pharmacodynamics analysis set includes all participants who: * received at least 21 days of study treatment \& * with lymphocyte count measurements at baseline and post-baseline (namely, one sample taken at least 21 days after the first study treatment intake and no later than 7 days after the last study treatment intake with no treatment interruption documented in the first 21 days) \& * with cenerimod plasma concentrations at Week 4 consistent with expectations.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12, end-of-treatment (EOT - up to 12 weeks), end-of-study (6 weeks after EOT)
Reported as:
Mean · 10^9 cells/L
Absolute Values of Total Lymphocyte Count at Each Analysis Visit
10^9 cells/LCenerimod 0.5 mg (Part A)Cenerimod 1 mg (Part A)Cenerimod 2 mg (Part A)Cenerimod 4 mg (Part B)Matching Placebo
Baseline visit1.37 ± 0.521.83 ± 0.791.62 ± 0.752.04 ± 0.801.66 ± 0.91
Week 2 visit1.24 ± 0.341.38 ± 0.491.19 ± 0.890.79 ± 0.441.44 ± 0.44
Week 4 visit1.09 ± 0.270.99 ± 0.380.73 ± 0.390.71 ± 0.491.31 ± 0.5
Week 8 visit1.08 ± 0.430.91 ± 0.400.73 ± 0.360.51 ± 0.281.49 ± 0.73
Week 12 visit1.11 ± 0.370.87 ± 0.340.76 ± 0.440.57 ± 0.211.33 ± 0.54
End-of-treatment visit1.11 ± 0.370.87 ± 0.340.76 ± 0.440.57 ± 0.211.34 ± 0.51
End-of-study visit1.42 ± 0.371.42 ± 0.581.35 ± 0.451.14 ± 0.521.71 ± 0.86
Post-hocTotal Lymphocyte Count Percent Change From Baseline to End-of-treatment (EOT)

Percentage change in total lymphocyte count from baseline to end-of-treatment (EOT). Percent change from baseline is defined as the absolute change from baseline divided by the baseline value (if the baseline value is \> 0) and then multiplied by 100. A negative change over time indicates that the number of peripheral circulating lymphocytes has decreased. The reduction of the total lymphocyte count over a treatment period indicates a pharmacodynamic effect. The modified pharmacodynamics analysis set includes all participants who: * received at least 21 days of study treatment \& * with lymphocyte count measurements at baseline and post-baseline (namely, one sample taken at least 21 days after the first study treatment intake and no later than 7 days after the last study treatment intake with no treatment interruption documented in the first 21 days) \& * with cenerimod plasma concentrations at Week 4 consistent with expectations.

Time frame:
Baseline to End of Treatment (EOT) (up to 12 weeks)
Reported as:
Mean · Percent change of total lymphocyte count
Total Lymphocyte Count Percent Change From Baseline to End-of-treatment (EOT)
Percent change of total lymphocyte countCenerimod 0.5 mg (Part A)Cenerimod 1 mg (Part A)Cenerimod 2 mg (Part A)Cenerimod 4 mg (Part B)Matching Placebo
Total Lymphocyte Count Percent Change From Baseline to End-of-treatment (EOT)-12.23 ± 34.29-47.76 ± 20.37-51.52 ± 22.53-69.27 ± 13.68-5.04 ± 39.22
Statistical analysis
  • Cenerimod 0.5 mg (Part A) vs Matching Placebo · ANCOVA · p = 0.1755 · Mean difference (final values): -13.214 · 95% CI -32.513 to 6.085
  • Cenerimod 1 mg (Part A) vs Matching Placebo · ANCOVA · p = 0.0003 · Mean difference (final values): -39.311 · 95% CI -59.552 to -19.069
  • Cenerimod 2 mg (Part A) vs Matching Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -47.278 · 95% CI -65.981 to -28.574
  • Cenerimod 4 mg (Part B) vs Matching Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -56.452 · 95% CI -77.585 to -35.320

Adverse events

Collected over All Adverse Events and Serious Adverse Events that occurred after the intake of the first study treatment and up to 6 weeks after study treatment discontinuation are reported, assessed up to 18 weeks.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cenerimod 0.5 mg0/12 (0%)0/12 (0%)5/12 (41.7%)
Cenerimod 1 mg0/12 (0%)0/12 (0%)5/12 (41.7%)
Cenerimod 2 mg0/13 (0%)0/13 (0%)6/13 (46.2%)
Cenerimod 4 mg0/13 (0%)0/13 (0%)5/13 (38.5%)
Matching Placebo0/17 (0%)1/17 (5.9%)9/17 (52.9%)
Most frequent serious events
Most frequent serious events
EventCenerimod 0.5 mgCenerimod 1 mgCenerimod 2 mgCenerimod 4 mgMatching Placebo
Pancreatitis chronicGastrointestinal disorders0/120/120/130/131/17
Cholecystitis chronicHepatobiliary disorders0/120/120/130/131/17
Post cholecystectomy syndromeHepatobiliary disorders0/120/120/130/131/17
Most frequent other events
Showing 10 of 47
Most frequent other events
EventCenerimod 0.5 mgCenerimod 1 mgCenerimod 2 mgCenerimod 4 mgMatching Placebo
NeutropeniaBlood and lymphatic system disorders2/120/120/130/131/17
Alanine aminotransferase increasedInvestigations2/120/120/130/130/17
HeadacheNervous system disorders2/120/120/130/131/17
NasopharyngitisInfections and infestations0/120/120/131/132/17
LymphopeniaBlood and lymphatic system disorders0/121/121/130/130/17
Abdominal discomfortGastrointestinal disorders1/120/120/130/130/17
GastroduodenitisGastrointestinal disorders0/121/120/130/130/17
NauseaGastrointestinal disorders1/121/120/130/130/17
Respiratory tract infection viralInfections and infestations0/121/120/130/131/17
Aspartate aminotransferase increasedInvestigations1/120/120/130/130/17

Baseline characteristics

Full analysis set (N=67). Pharmacodynamic analysis set (PD set, N=64) at least 21 days of treatment, with lymphocyte count measurements at baseline and post-baseline. Modified pharmacodynamic analysis set (N=60) excluded 4 patients from PD set with low, or below the lower limit of quantification (BLQ) Ctrough levels.

Age, Continuous
Age, Continuous(years)Cenerimod 0.5 mg (Part A)Cenerimod 1 mg (Part A)Cenerimod 2 mg (Part A)Cenerimod 4 mg (Part B)Matching Placebo (Part A and Part B)Total
Full analysis set41.4 ± 13.237.0 ± 6.439.2 ± 11.841.7 ± 8.141.0 ± 9.540.1 ± 9.9
Pharmacodynamic analysis set41.4 ± 13.238.1 ± 5.439.2 ± 11.841.7 ± 8.141.8 ± 9.240.6 ± 9.8
Modified pharmacodynamics analysis set41.4 ± 13.238.1 ± 5.439.2 ± 11.841.9 ± 8.641.8 ± 9.240.6 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Cenerimod 0.5 mg (Part A)Cenerimod 1 mg (Part A)Cenerimod 2 mg (Part A)Cenerimod 4 mg (Part B)Matching Placebo (Part A and Part B)Total
Full analysis set — Female111212101661
Full analysis set — Male101316
Pharmacodynamic analysis set — Female111012101659
Pharmacodynamic analysis set — Male101305
Modified pharmacodynamic analysis set — Female11101271656
Modified pharmacodynamic analysis set — Male101204
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cenerimod 0.5 mg (Part A)Cenerimod 1 mg (Part A)Cenerimod 2 mg (Part A)Cenerimod 4 mg (Part B)Matching Placebo (Part A and Part B)Total
Hispanic or Latino000000
Not Hispanic or Latino121213131767
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cenerimod 0.5 mg (Part A)Cenerimod 1 mg (Part A)Cenerimod 2 mg (Part A)Cenerimod 4 mg (Part B)Matching Placebo (Part A and Part B)Total
Full analysis set — American Indian or Alaska Native000000
Full analysis set — Asian000000
Full analysis set — Native Hawaiian or Other Pacific Islander000000
Full analysis set — Black or African American000022
Full analysis set — White121213131565
Full analysis set — More than one race000000
Full analysis set — Unknown or Not Reported000000
Pharmacodynamic analysis set — American Indian or Alaska Native000000
Pharmacodynamic analysis set — Asian000000
Pharmacodynamic analysis set — Native Hawaiian or Other Pacific Islander000000
Pharmacodynamic analysis set — Black or African American000022
Pharmacodynamic analysis set — White121013131462
Pharmacodynamic analysis set — More than one race000000
Pharmacodynamic analysis set — Unknown or Not Reported000000
Modified pharmacodynamic analysis set — American Indian or Alaska Native000000
Modified pharmacodynamic analysis set — Asian000000
Modified pharmacodynamic analysis set — Native Hawaiian or Other Pacific Islander000000
Modified pharmacodynamic analysis set — Black or African American000022
Modified pharmacodynamic analysis set — White12101391458
Modified pharmacodynamic analysis set — More than one race000000
Modified pharmacodynamic analysis set — Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)Cenerimod 0.5 mg (Part A)Cenerimod 1 mg (Part A)Cenerimod 2 mg (Part A)Cenerimod 4 mg (Part B)Matching Placebo (Part A and Part B)Total
United States110024
Ukraine312129
Georgia211116
Belarus012227
Bulgaria3227519
Russia3662522
Body mass index
Body mass index(kg/m^2)Cenerimod 0.5 mg (Part A)Cenerimod 1 mg (Part A)Cenerimod 2 mg (Part A)Cenerimod 4 mg (Part B)Matching Placebo (Part A and Part B)Total
Full analysis set25.2 ± 5.127.4 ± 8.026.0 ± 5.127.5 ± 4.725.4 ± 6.826.3 ± 6.0
Pharmacodynamic analysis set25.2 ± 5.128.8 ± 8.126.0 ± 5.127.5 ± 4.725.5 ± 7.026.5 ± 6.1
Modified pharmacodynamic analysis set25.2 ± 5.128.8 ± 8.126.0 ± 5.128.3 ± 5.425.5 ± 7.026.5 ± 6.2
Disease history time from first Systemic Lupus Erythematosus symptoms
Disease history time from first Systemic Lupus Erythematosus symptoms(years)Cenerimod 0.5 mg (Part A)Cenerimod 1 mg (Part A)Cenerimod 2 mg (Part A)Cenerimod 4 mg (Part B)Matching Placebo (Part A and Part B)Total
Full analysis set3.7 (1.6 to 23.7)8.2 (0.6 to 22.5)6.7 (1.4 to 20.9)4.6 (0.8 to 10.5)7.9 (1.1 to 22.1)6.0 (0.6 to 23.7)
Pharmacodynamic analysis set3.7 (1.6 to 23.7)9.2 (0.6 to 22.5)6.7 (1.4 to 20.9)4.6 (0.8 to 10.5)7.9 (1.7 to 22.1)6.2 (0.6 to 23.7)
Modified pharmacodynamic analysis set3.7 (1.6 to 23.7)9.2 (0.6 to 22.5)6.7 (1.4 to 20.9)3.2 (0.8 to 6.7)7.9 (1.7 to 22.1)6.2 (0.6 to 23.7)
Time from first Systemic Lupus Erythematosus diagnosis
Time from first Systemic Lupus Erythematosus diagnosis(years)Cenerimod 0.5 mg (Part A)Cenerimod 1 mg (Part A)Cenerimod 2 mg (Part A)Cenerimod 4 mg (Part B)Matching Placebo (Part A and Part B)Total
Full analysis set2.4 (1.4 to 23.7)6.2 (0.5 to 22.3)4.5 (1.3 to 17.0)2.9 (0.6 to 9.2)4.9 (0.5 to 21.4)3.8 (0.5 to 23.7)
Pharmacodynamic analysis set2.4 (1.4 to 23.7)5.8 (0.5 to 22.3)4.5 (1.3 to 17.0)2.9 (0.6 to 9.2)5.0 (0.5 to 21.4)3.6 (0.5 to 23.7)
Modified pharmacodynamic analysis set2.4 (1.4 to 23.7)5.8 (0.5 to 22.3)4.5 (1.3 to 17.0)1.3 (0.6 to 5.2)5.0 (0.5 to 21.4)3.6 (0.5 to 23.7)

2 further baseline measures are reported on the registry.

08

Study locations

18 sites
  • Investigator Site
    Anniston, Alabama 36207, United States
  • Investigator Site
    Clearwater, Florida 33765, United States
  • Investigator Site
    Minsk, 220116, Belarus
  • Investigator Site
    Minsk, 223041, Belarus
  • Investigator Site
    Vitebsk, 210037, Belarus
  • Investigator Site
    Plovdiv, 4000, Bulgaria
  • Investigator Site
    Plovdiv, 4002, Bulgaria
  • Investigator Site
    Sofia, 1612, Bulgaria
  • Investigator Site
    Tbilisi, 0186, Georgia
  • Investigator Site
    Kemerovo, 650066, Russia
  • Investigator Site
    Kursk, 305007, Russia
  • Investigator Site
    Omsk, 644111, Russia
  • Investigator Site
    Orenburg, 460018, Russia
  • Investigator Site
    Smolensk, 214025, Russia
  • Investigator Site
    Vladimir, 600023, Russia
  • Investigator Site
    Vinnytsia, 21018, Ukraine
  • Investigator Site
    Vinnytsia, 21029, Ukraine
  • Investigator Site
    Zaporizhia, 69600, Ukraine
09

References and documents

Publications

  • Hermann V, Batalov A, Smakotina S, Juif PE, Cornelisse P. First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lupus Sci Med. 2019 Nov 9;6(1):e000354. doi: 10.1136/lupus-2019-000354. eCollection 2019. PubMed 31798918 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Jan 2017, 19 months.

Results were first posted in Feb 2020, 3 years 1 month after primary completion. A results delay was requested in Feb 2018.

Of 37 phase 1/2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2015
First posted
Jun 16, 2015
StartActual
Jun 1, 2015
Primary completionActual
Jan 23, 2017
CompletionActual
Feb 28, 2017
Results delay requested
Feb 20, 2018
Results first posted
Feb 26, 2020
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02472795
Responsible party
Sponsor
First posted
Jun 16, 2015
Start date
Jun 1, 2015
Primary completion
Jan 23, 2017
Completion
Feb 28, 2017
Results posted
Feb 26, 2020
Last update
Jul 29, 2026

Study contacts

Clinical Trials
study director · Viatris Innovation GmbH

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cenerimod

Start the discussion